What this site is
Doctor PT-141 is an independent editorial project that publishes summaries of the peer-reviewed research literature on bremelanotide (PT-141). We read the trials, the FDA label, the pharmacology papers, and the recent extension-program publications, and we write the page that we wished existed when we started — a single quiet place where the actual evidence is collected, sourced, and explained in plain English.
The work is editorial commentary on publicly available science. Every quantitative claim on the site is tied to a numbered reference. The references page lists every source with a DOI or a stable URL. Inline citation markers across every page link directly to the corresponding entry, and the on-page hover previews are powered by a small open-source tooltip library — they are designed to make the source visible without breaking the reading flow.
What this site is not
We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. We do not refer readers to any pharmacy, telehealth service, compounding facility, or supplier, and we have no commercial relationship with any vendor or manufacturer of bremelanotide or any related compound.
The word 'Doctor' in the domain name is editorial framing — a position the publisher occupies relative to the published literature, not a claim about the site's services. There is no Doctor PT-141 clinic, no Doctor PT-141 prescribing physician, and no Doctor PT-141 product. We do not write prescriptions, conduct consultations, or evaluate individual patients. Anyone considering bremelanotide for any reason should speak with a licensed clinician who knows their medical history; nothing on this site is a substitute for that conversation.
How the page is sourced
Citations are restricted to peer-reviewed journals (Obstetrics & Gynecology, Journal of Women's Health, The Journal of Clinical Investigation, Diabetes Obesity and Metabolism, CNS Spectrums, Drugs, Neurology International, Proceedings of the National Academy of Sciences, the Journal of Sexual Medicine, International Journal of Impotence Research, Urology, Anticancer Research), FDA-approved labeling and regulatory documents, ClinicalTrials.gov registry entries, and named investigator or sponsor press releases when those are the primary source for in-progress Phase 2 data (BMT-801 obesity, combination-ED Phase 2). We do not cite forum posts, anonymous blogs, vendor marketing materials, or other secondary sources.
Where the literature is uncertain or contested, the page says so. The modest absolute effect size on the FSFI-Desire endpoint (~0.35 LS-mean difference), the debate about clinical meaningfulness in the HSDD literature, the absence of adequately powered modern trials in male and postmenopausal populations, and the preclinical status of the oncology work are all noted in the relevant sections.
Names and labels
We use only generic names throughout the site: 'PT-141' and 'bremelanotide' interchangeably (they refer to the same molecule). We do not use the brand name for the FDA-approved injectable product because the goal of the page is to discuss the molecule and the trial record, not to promote any specific commercial product. The same convention applies to other compounds referenced on the site: PDE5 inhibitors are referred to as sildenafil and tadalafil by their generic names, and the GLP-1/GIP dual agonist discussed in the obesity section is referred to as tirzepatide rather than by any brand name.
